These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 138609)

  • 21. [Comparative testing of diflucortolon-21-valerate creme and hydrocortisone-17-butyrate creme in patients with dermatoses].
    Grejs J
    Ther Ggw; 1978 Dec; 117(12):1930-7. PubMed ID: 725810
    [No Abstract]   [Full Text] [Related]  

  • 22. [Double blind study with diflucortolone valerianate and chlorquinaldol, comparison with placebo in various dermatosis].
    Arias Gómez O
    Alergia; 1977 Apr; 24(2):85-9. PubMed ID: 331993
    [No Abstract]   [Full Text] [Related]  

  • 23. Comparative blanching activities of proprietary diflucortolone valerate topical preparations.
    Coleman GL; Kanfer I; Haigh JM
    Dermatologica; 1978; 156(4):224-30. PubMed ID: 342295
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Comparative studies on Bi-Nerisona cream (diflucortolone valerinate + chlorquinaldol) and on a combination preparation (betamethasone valerinate + gentamicin + tolnaftate + clioquinol) in a double-blind trial].
    Hernández MS
    Z Hautkr; 1978 Jul; 53(13):453-8. PubMed ID: 150142
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Multicentre-clinical trial of the novel corticosteroid diflucortolone valerate in the forms of cream, ointment and fatty ointment. Part II: Comparative study with several commercial preparations (author's transl)].
    Reckers VR; Wendt H
    Arzneimittelforschung; 1976; 26(7b):1504-9. PubMed ID: 795434
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of a midpotency topical corticosteroid and the clinical relevance of formulation characteristics in the management of commonly encountered eczematous and inflammatory dermatoses in adults and children: focus on the pharmacologic properties of clocortolone pivalate 0.1% cream.
    Del Rosso JQ; Kircik LH
    J Drugs Dermatol; 2013 Feb; 12(2):s5-s10. PubMed ID: 23377405
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Difluocortolone valerate for topical use in dermatology].
    Consigli CA; González W
    Z Hautkr; 1976; 51 Suppl 1():30-2. PubMed ID: 795184
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Treatment of chronic eczemas. The comparative efficacy of two creams.
    Doherty JC; MacRae KD; Platt NE
    Practitioner; 1979 Apr; 222(1330):561-3. PubMed ID: 382173
    [No Abstract]   [Full Text] [Related]  

  • 29. [Difluocortolone valerate in dermatology].
    Azar A
    Z Hautkr; 1976; 51 Suppl 1():20-2. PubMed ID: 795181
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A multicentric clinical trial with 0.1% diflucortolone valerate in Thailand.
    Bunyaratavej K; Hoppe G; Kotrajaras R; Rojananondh C; Siriyong D; Somprasong B; Tanprasert C; Vipakoon A; Vipulyasekha S
    J Med Assoc Thai; 1977 Aug; 60(8):353-61. PubMed ID: 908897
    [No Abstract]   [Full Text] [Related]  

  • 31. [Ertolan, a new corticoid-antihistamine therapeutic combination in ointment form].
    Kühnau W
    Med Klin; 1967 Jun; 62(26):1023-5. PubMed ID: 4232992
    [No Abstract]   [Full Text] [Related]  

  • 32. [The use of difluocortolone valerate for various dermatoses].
    Saraceno EF; Viglioglia A
    Z Hautkr; 1976; 51 Suppl 1():60-1. PubMed ID: 795178
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Results of a multi-center, international clinical trial of difluocortolone valerate (Nerisona)].
    Langen M; Hernandez MS
    Z Hautkr; 1976; 51 Suppl 1():1-16. PubMed ID: 795179
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Therapeutic effect and effect on the pituitary adrenal functions of fluocortine-butylester in eczema during childhood (author's transl)].
    Favrod-Coune E; Sizonenko PC; Paunier L; Varonier H; Hunziker N
    Dermatologica; 1978; 157(5):297-9. PubMed ID: 150351
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Treatment of inflammatory dermatoses with difluocortolone valerate].
    Filho JL; Lacet IG; Calheiros de Lima ME; Santos Oliveira VL
    Z Hautkr; 1976; 51 Suppl 1():40-2. PubMed ID: 795187
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Report on clinical experience with a new corticosteroid in dermatoses].
    Gatermann B
    Med Welt; 1977 Feb; 28(6):296-300. PubMed ID: 321909
    [No Abstract]   [Full Text] [Related]  

  • 37. Local treatment of psoriasis and eczema with betamethasone-17,21-dipropionate (Diproderm cream): a double-blind comparsion with fluocortolone caproate, fluocortolone pivalate (Ultralanum cream).
    Nordwall C
    Curr Ther Res Clin Exp; 1974 Aug; 16(8):798-803. PubMed ID: 4217246
    [No Abstract]   [Full Text] [Related]  

  • 38. [Clinical research on a new corticoid-containing topical drug].
    Sturde HC
    Z Hautkr; 1976 Aug; 51(16):673-8. PubMed ID: 969808
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A new topical corticosteroid.
    Med Lett Drugs Ther; 1982 Nov; 24(623):103-4. PubMed ID: 7144689
    [No Abstract]   [Full Text] [Related]  

  • 40. A test of the half-side comparative design in the clinical evaluation of topical steroids, using diflucortolone and betamethasone creams.
    August PJ; Platt NE; Wiseman RA
    Br J Clin Pract; 1985 Oct; 39(10):383-7. PubMed ID: 3907679
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.